The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic
This study employed sero-epidemiological methods to estimate the incidence of pertussis within a healthy population located in eastern China. The aim was to gain deeper insights into the epidemiological characteristics and burden of pertussis within the country. Blood samples were collected from hea...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2331438 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687366111854592 |
|---|---|
| author | Xiang Sun Tingting Zhang Jinning Sun Juan Zhou Qiang Chen Chengmei Jia Yan Xu Yun Wu Zhiguo Wang Wen Wang |
| author_facet | Xiang Sun Tingting Zhang Jinning Sun Juan Zhou Qiang Chen Chengmei Jia Yan Xu Yun Wu Zhiguo Wang Wen Wang |
| author_sort | Xiang Sun |
| collection | DOAJ |
| description | This study employed sero-epidemiological methods to estimate the incidence of pertussis within a healthy population located in eastern China. The aim was to gain deeper insights into the epidemiological characteristics and burden of pertussis within the country. Blood samples were collected from healthy individuals in Jiangsu Province between June 2019 and December 2022. The levels of IgG antibodies against pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) in the serum were quantitatively measured using enzyme-linked immunosorbent assay (ELISA). Additionally, pertussis case data reported in Jiangsu Province were collected from the China Information System for Disease Control and Prevention and compared with the results of this study. In 2022, the reported incidence of pertussis stood at 1.0 per 100,000 individuals, marking the highest rate observed in the past two decades. Among 1,909 patients examined, the geometric mean concentration (GMC) of anti-PT IgG antibody was 20.2 (18.5–21.9) IU/ml, while that of anti-FHA IgG antibody was 27.0 (25.4–28.7) IU/ml. The IgG-PT and IgG-FHA seropositivity rate (>20.0 IU/ml) was highest in the 1 ~ 2 y old group and decreased rapidly to the lowest in the 3 ~ 4 y old group and then increased gradually with age. The estimated rate of pertussis infection based on seroprevalence was approximately 25,625‐fold higher than the reported notification rate in the ≥15 year age group. Our findings highlight decreased immunity post-vaccination, stressing the importance of additional booster shots for adolescents and adults to maintain immunity and reduce severe illness. Additionally, they offer vital guidance for policymakers to enhance immunization strategies. |
| format | Article |
| id | doaj-art-19c76aad04334e9e92d0aee266507db1 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-19c76aad04334e9e92d0aee266507db12025-08-20T03:22:21ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2331438The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemicXiang Sun0Tingting Zhang1Jinning Sun2Juan Zhou3Qiang Chen4Chengmei Jia5Yan Xu6Yun Wu7Zhiguo Wang8Wen Wang9Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaMedical Record Office, Children’s Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Expanded Program on Immunization, Nanjing Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Gaogang Center for Disease Control and Prevention, Taizhou, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, ChinaDepartment of Rheumatology and Immunology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian, ChinaThis study employed sero-epidemiological methods to estimate the incidence of pertussis within a healthy population located in eastern China. The aim was to gain deeper insights into the epidemiological characteristics and burden of pertussis within the country. Blood samples were collected from healthy individuals in Jiangsu Province between June 2019 and December 2022. The levels of IgG antibodies against pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) in the serum were quantitatively measured using enzyme-linked immunosorbent assay (ELISA). Additionally, pertussis case data reported in Jiangsu Province were collected from the China Information System for Disease Control and Prevention and compared with the results of this study. In 2022, the reported incidence of pertussis stood at 1.0 per 100,000 individuals, marking the highest rate observed in the past two decades. Among 1,909 patients examined, the geometric mean concentration (GMC) of anti-PT IgG antibody was 20.2 (18.5–21.9) IU/ml, while that of anti-FHA IgG antibody was 27.0 (25.4–28.7) IU/ml. The IgG-PT and IgG-FHA seropositivity rate (>20.0 IU/ml) was highest in the 1 ~ 2 y old group and decreased rapidly to the lowest in the 3 ~ 4 y old group and then increased gradually with age. The estimated rate of pertussis infection based on seroprevalence was approximately 25,625‐fold higher than the reported notification rate in the ≥15 year age group. Our findings highlight decreased immunity post-vaccination, stressing the importance of additional booster shots for adolescents and adults to maintain immunity and reduce severe illness. Additionally, they offer vital guidance for policymakers to enhance immunization strategies.https://www.tandfonline.com/doi/10.1080/21645515.2024.2331438Pertussisseroepidemiologyimmunological responsevaccinationanti-PT IgGanti-FHA IgG |
| spellingShingle | Xiang Sun Tingting Zhang Jinning Sun Juan Zhou Qiang Chen Chengmei Jia Yan Xu Yun Wu Zhiguo Wang Wen Wang The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic Human Vaccines & Immunotherapeutics Pertussis seroepidemiology immunological response vaccination anti-PT IgG anti-FHA IgG |
| title | The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic |
| title_full | The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic |
| title_fullStr | The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic |
| title_full_unstemmed | The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic |
| title_short | The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic |
| title_sort | seroepidemiology of immunoglobulin g antibodies against pertussis toxin and filamentous hemagglutinin in the east of china during the covid 19 pandemic |
| topic | Pertussis seroepidemiology immunological response vaccination anti-PT IgG anti-FHA IgG |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2331438 |
| work_keys_str_mv | AT xiangsun theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT tingtingzhang theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT jinningsun theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT juanzhou theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT qiangchen theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT chengmeijia theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT yanxu theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT yunwu theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT zhiguowang theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT wenwang theseroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT xiangsun seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT tingtingzhang seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT jinningsun seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT juanzhou seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT qiangchen seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT chengmeijia seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT yanxu seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT yunwu seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT zhiguowang seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic AT wenwang seroepidemiologyofimmunoglobulingantibodiesagainstpertussistoxinandfilamentoushemagglutininintheeastofchinaduringthecovid19pandemic |